Erick Wayne  Devinney net worth and biography

Erick Devinney Biography and Net Worth

Insider of AxoGen

Mr. DeVinney joined Axogen in April of 2007. During his tenure, he has held positions of progressive responsibility in Clinical Research, Research and Development, Product Development, Medical Education and Medical Affairs. Mr. DeVinney has more than 17 years of experience driving innovation in peripheral nerve injury diagnosis and repair, including clinical and regulatory development strategies, portfolio development and scientific thought leadership. He has a diverse background, including academic research and the development of tissue technologies, medical devices, pharmaceuticals and biologics. Mr. DeVinney has been involved in research at the Virginia Commonwealth University Medical College of Virginia Hospitals, University of Utrecht, National Clinical Research, PRA International and Angiotech. He has been involved in the successful submission of numerous IDE, NDA, BLA and 510(k) applications. Mr. DeVinney also serves as a Board Member for the Global Nerve Foundation. He has a B.S. degree in Chemistry from Virginia Commonwealth University.

What is Erick Wayne Devinney's net worth?

The estimated net worth of Erick Wayne Devinney is at least $3.73 million as of March 19th, 2025. Devinney owns 217,762 shares of AxoGen stock worth more than $3,730,263 as of May 3rd. This net worth approximation does not reflect any other assets that Devinney may own. Learn More about Erick Wayne Devinney's net worth.

How do I contact Erick Wayne Devinney?

The corporate mailing address for Devinney and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at investorrelations@axogeninc.com. Learn More on Erick Wayne Devinney's contact information.

Has Erick Wayne Devinney been buying or selling shares of AxoGen?

Erick Wayne Devinney has not been actively trading shares of AxoGen over the course of the past ninety days. Most recently, Erick Wayne Devinney sold 15,111 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a transaction totalling $264,442.50. Following the completion of the sale, the insider now directly owns 217,762 shares of the company's stock, valued at $3,810,835. Learn More on Erick Wayne Devinney's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes P Burke (Director), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 2 times. They sold a total of 20,111 shares worth more than $364,542.50. The most recent insider tranaction occured on March, 19th when insider Erick Wayne Devinney sold 15,111 shares worth more than $264,442.50. Insiders at AxoGen own 7.0% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 3/19/2025.

Erick Wayne Devinney Insider Trading History at AxoGen

See Full Table

Erick Wayne Devinney Buying and Selling Activity at AxoGen

This chart shows Erick Wayne Devinney's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $17.13
Low: $16.40
High: $17.17

50 Day Range

MA: $17.21
Low: $15.18
High: $20.01

2 Week Range

Now: $17.13
Low: $5.55
High: $21.00

Volume

535,272 shs

Average Volume

431,968 shs

Market Capitalization

$759.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19